Higgons John Duncan 4
4 · Jounce Therapeutics, Inc. · Filed Jun 21, 2018
Insider Transaction Report
Form 4
Higgons John Duncan
Director
Transactions
- Award
Stock Option (Right to Buy)
2018-06-19+13,550→ 13,550 totalExercise: $7.92Exp: 2028-06-19→ Common Stock (13,550 underlying)
Footnotes (1)
- [F1]The option will vest in equal quarterly installments during the four quarters following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors.